AT1 Stock Overview
Engages in the development and sale of medical devices worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Atomo Diagnostics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.019 |
| 52 Week High | AU$0.06 |
| 52 Week Low | AU$0.018 |
| Beta | 0.89 |
| 11 Month Change | -13.64% |
| 3 Month Change | -9.52% |
| 1 Year Change | -13.64% |
| 33 Year Change | -90.50% |
| 5 Year Change | n/a |
| Change since IPO | -95.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| AT1 | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -9.5% | -0.4% | 0.9% |
| 1Y | -13.6% | 13.5% | 17.7% |
Return vs Industry: AT1 underperformed the Australian Medical Equipment industry which returned 13.5% over the past year.
Return vs Market: AT1 underperformed the Australian Market which returned 17.7% over the past year.
Price Volatility
| AT1 volatility | |
|---|---|
| AT1 Average Weekly Movement | 8.3% |
| Medical Equipment Industry Average Movement | 9.2% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: AT1 has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: AT1's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | John Kelly | atomodiagnostics.com |
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers rapid diagnostic test devices for HIV screening, pregnancy test, and respiratory test. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Atomo Diagnostics Limited Fundamentals Summary
| AT1 fundamental statistics | |
|---|---|
| Market cap | AU$12.14m |
| Earnings (TTM) | -AU$6.85m |
| Revenue (TTM) | AU$4.09m |
3.0x
P/S Ratio-1.8x
P/E RatioIs AT1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AT1 income statement (TTM) | |
|---|---|
| Revenue | AU$4.09m |
| Cost of Revenue | AU$2.65m |
| Gross Profit | AU$1.44m |
| Other Expenses | AU$8.28m |
| Earnings | -AU$6.85m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 35.16% |
| Net Profit Margin | -167.57% |
| Debt/Equity Ratio | 0% |
How did AT1 perform over the long term?
See historical performance and comparison